Spots Global Cancer Trial Database for Safety of PCI-32765 in Chronic Lymphocytic Leukemia
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety of PCI-32765 in Chronic Lymphocytic Leukemia
Official Title: A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
Study ID: NCT01105247
Interventions
Study Description
Brief Summary: The purpose of this study is to establish the safety and efficacy of orally administered PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Stanford University School of Medicine, Stanford, California, United States
New York Presbyterian Hosptial Cornell Med Center, New York, New York, United States
The Ohio State University, Columbus, Ohio, United States
Willamette Valley Cancer Institute and Research Center, Springfield, Oregon, United States
Sarah Cannon, Nashville, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
Texas Oncology - Tyler, Tyler, Texas, United States
University of Vermont and Fletcher Allen Health Care, Burlington, Vermont, United States
Northwest Cancer Specialists, P.C., Vancouver, Washington, United States
Yakima Valley Memorial, Yakima, Washington, United States
Contact Details
Name: Danelle James, M.D., M.A.S
Affiliation: Pharmacyclics LLC.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
